These goals demand greater attention and a much needed, but so far absent, coordinated global response strategy.
Patients who are eligible for the treatment have to take the drug within five days of infection.
Still, infectious disease experts say the findings are exciting and hopeful.
Michela Buttignol / Getty Images
At a time when other resources are limited, fingers are crossed that the antiviral can offer a cure.
Now, theres yet another potential reason.
Paxlovid works by shortening the duration of viral replication in a person infected with COVID-19.
Long COVID comes up whenever the virus stays in the body too long.
The researchers also evaluated a large number of people, which may increase the validity of their results.
He added that the study is ongoing and the results have yet to be released.
More studies and trials will be needed to confirm whether Paxlovid has a clinical impact on long COVID development.
A new study suggests that Paxlovid might be able to prevent long COVID as well.
For the most recent updates on COVID-19, visit ourcoronavirus news page.
Xie Y, Choi T, Al-Aly Z.Nirmatrelvir and the risk of post-acute sequelae of COVID-19.medRxiv.
Preprint posted online November 5, 2022. doi:10.1101/2022.11.03.22281783
